Aging
Navigate
Research Article|Volume 8, Issue 9|pp 1952—1978

PPARβ/δ selectively regulates phenotypic features of age-related macular degeneration

Mayur Choudhary1, Jin-dong Ding1, Xiaoping Qi2, Michael E. Boulton2, Pei-Li Yao3, Jeffrey M. Peters3, Goldis Malek1,4
  • 1Department of Ophthalmology, Duke University School of Medicine, Durham, NC 27703, USA
  • 2Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
  • 3Department of Veterinary and Biomedical Sciences, The Pennsylvania State University, University Park, PA 16802, USA
  • 4Department of Pathology, Duke University School of Medicine, Durham, NC 27703, USA
Received: June 23, 2016Accepted: August 26, 2016Published: September 8, 2016

Abstract

Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) is a nuclear receptor that regulates differentiation, inflammation, lipid metabolism, extracellular matrix remodeling, and angiogenesis in multiple tissues. These pathways are also central to the pathogenesis of age-related macular degeneration (AMD), the leading cause of vision loss globally. With the goal of identifying signaling pathways that may be important in the development of AMD, we investigated the impact of PPARβ/δ activation on ocular tissues affected in the disease. PPARβ/δ is expressed and can be activated in AMD vulnerable cells, including retinal pigment epithelial (RPE) and choroidal endothelial cells. Further, PPARβ/δ knockdown modulates AMD-related pathways selectively. Specifically, genetic ablation of Pparβ/δ in aged mice resulted in exacerbation of several phenotypic features of early dry AMD, but attenuation of experimentally induced choroidal neovascular (CNV) lesions. Antagonizing PPARβ/δ in both in vitro angiogenesis assays and in the in vivo experimentally induced CNV model, inhibited angiogenesis and angiogenic pathways, while ligand activation of PPARβ/δ, in vitro, decreased RPE lipid accumulation, characteristic of dry AMD. This study demonstrates for the first time, selective regulation of a nuclear receptor in the eye and establishes that selective targeting of PPARβ/δ may be a suitable strategy for treatment of different clinical sub-types of AMD.